US 12,115,280 B2
Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates
Jeffrey S. Dove, Gualala, CA (US); and Tara J. Tod, Tustin, CA (US)
Assigned to EDWARDS LIFESCIENCES CORPORATION, Irvine, CA (US)
Filed by Edwards Lifesciences Corporation, Irvine, CA (US)
Filed on Dec. 18, 2020, as Appl. No. 17/127,281.
Application 17/127,281 is a continuation of application No. 14/563,866, filed on Dec. 8, 2014, abandoned.
Application 14/563,866 is a continuation of application No. 13/163,557, filed on Jun. 17, 2011, granted, now 8,906,601, issued on Dec. 9, 2014.
Claims priority of provisional application 61/355,943, filed on Jun. 17, 2010.
Prior Publication US 2021/0100931 A1, Apr. 8, 2021
Int. Cl. A61L 27/36 (2006.01); A61L 27/50 (2006.01); A61L 27/54 (2006.01)
CPC A61L 27/3687 (2013.01) [A61L 27/50 (2013.01); A61L 27/54 (2013.01); A61L 2430/20 (2013.01); A61L 2430/40 (2013.01)] 34 Claims
OG exemplary drawing
 
1. A method of manufacturing a bioprosthetic implant for a human host, the method comprising:
decellularizing a bioprosthetic tissue;
treating the bioprosthetic tissue with a first oxidizing agent solution to convert at least a portion of vicinal diol moieties of an antigenic epitope to pendant aldehydes;
subsequent to treating the bioprosthetic tissue with the first oxidizing agent solution, treating the bioprosthetic tissue having the pendant aldehydes with a second oxidizing agent solution comprising sodium chlorite (NaClO2) or hydrogen peroxide to convert, at least a portion of the pendant aldehydes to carboxylic acids;
subsequent to treating the bioprosthetic tissue with the second oxidizing agent solution, treating the bioprosthetic tissue having the carboxylic acids with a capping agent selected from the group consisting of N-hydroxysuccinamide and N-hydroxysulfosuccinamide to convert, at least a portion of the carboxylic acids to esters;
subsequent to treating the bioprosthetic tissue with the capping agent, treating the bioprosthetic tissue having the esters with a carbodiimide stabilizing agent to convert at least a portion of the esters to amides; and
at least partially fabricating a bioprosthetic implant with the bioprosthetic tissue having the amides;
wherein the bioprosthetic tissue is a non-human, mammalian tissue.